Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

• Published in: The Lancet (British edition) Vol. 389; no. 10082; pp. 1919 - 1929
• Main Authors: Vestbo, Jørgen, Prof, Papi, Alberto, Prof, Corradi, Massimo, Prof, Blazhko, Viktor, MD, Montagna, Isabella, MSc, Francisco, Catherine, MSc, Cohuet, Géraldine, MSc, Vezzoli, Stefano, MSc, Scuri, Mario, MD, Singh, Dave, Prof
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 13.05.2017; Elsevier Limited
• Subjects: Acetylcholine receptors (muscarinic); Acute coronary syndromes; Air flow; Angina pectoris; Antagonist drugs; Bronchodilators; Cardiomyopathy; Cardiovascular disease; Chronic obstructive pulmonary disease; Clinical trials; Coronary vessels; Corticosteroids; Disease control; Dosage; Double-blind studies; Evidence-based medicine; Formoterol; Heart attacks; Inhalation; Inhalers; Interactive systems; Internal Medicine; Lung diseases; Obstructive lung disease; Patients; Pneumonia; Population; Powder; Quality of life; Randomization; Respiration; Respiratory therapy; Therapy; Germany

Summary Background Limited data are available for the efficacy of triple therapy with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD). We compared treatment with extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrroniu...